The PARP inhibitor ABT-888 (Veliparib) was purchased from Active Biochem and diluted in PBS from frozen stock for experiments. For in vivo experiments, the PARP inhibitor was administered orally at indicated concentrations in a 20 mL volume using a pipette.
The CTLA-4 hybridoma (clone UC10-4F10-1) and IFNγ hybridoma (clone R4-6A2) were purchased from the ATCC. PD-1 (clone C1-G4) and PD-L1 (B7-H1, clone 10B5) hybridomas were kindly provided by Dr. Lieping Chen (Yale University). Hybridomas were grown, and monoclonal antibodies (mAb) were purified as previously described (23 (link)). For in vivo experiments, 100 mg of CTLA-4, 300 mg of PD-1, or PD-L1 mAbs diluted in 300 mL of PBS was injected intraperitoneally at the time points indicated.
Purified tumor necrosis factor-α (TNFα) neutralizing mAb (clone XT3.11) was purchased from BioXcell. Neutralizing anti- bodies to IFNγ or TNFα (0.5 mg) were injected intraperitoneally every 4 days beginning on day 7 after tumor challenge, as previously described (24 (link), 25 (link)). Mouse recombinant TNFα was purchased from eBioscience. Recombinant human TNFα, recombinant mouse IFNγ, and recombinant human IFNγ were purchased from BioLegend.
The CTLA-4 hybridoma (clone UC10-4F10-1) and IFNγ hybridoma (clone R4-6A2) were purchased from the ATCC. PD-1 (clone C1-G4) and PD-L1 (B7-H1, clone 10B5) hybridomas were kindly provided by Dr. Lieping Chen (Yale University). Hybridomas were grown, and monoclonal antibodies (mAb) were purified as previously described (23 (link)). For in vivo experiments, 100 mg of CTLA-4, 300 mg of PD-1, or PD-L1 mAbs diluted in 300 mL of PBS was injected intraperitoneally at the time points indicated.
Purified tumor necrosis factor-α (TNFα) neutralizing mAb (clone XT3.11) was purchased from BioXcell. Neutralizing anti- bodies to IFNγ or TNFα (0.5 mg) were injected intraperitoneally every 4 days beginning on day 7 after tumor challenge, as previously described (24 (link), 25 (link)). Mouse recombinant TNFα was purchased from eBioscience. Recombinant human TNFα, recombinant mouse IFNγ, and recombinant human IFNγ were purchased from BioLegend.
